Design Therapeutics, Inc. (DSGN) — Financial statements
Income statement, balance sheet, and cash flow for Design Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.62↑4.4% | 0.60↑11.0% | 0.54↑15.2% | 0.47 | 0.00 | |
| Gross Profit | -0.62↓4.4% | -0.60↓11.0% | -0.54↓15.2% | -0.47 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 59↑33.3% | 44↓22.3% | 57↑17.4% | 49↑96.2% | 25 | |
| General & Administrative Expenses | 20↑12.8% | 18↓14.6% | 21↑11.3% | 19↑71.7% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↑12.8% | 18↓14.6% | 21↑11.3% | 19↑71.7% | 11 | |
| Other Expenses | -0.62↓4.4% | -0.60↓11.0% | -0.54↓15.2% | -0.47 | 0.00 | |
| Operating Expenses | 79↑27.6% | 62↓20.4% | 78↑15.7% | 67↑87.3% | 36 | |
| Total Costs & Expenses | 79↑27.4% | 62↓20.2% | 78↑15.7% | 68↑88.6% | 36 | |
| Operating Results | ||||||
| Operating Income | -79↓27.4% | -62↑20.2% | -78↓15.7% | -68↓88.6% | -36 | |
| Depreciation & Amortization | 0.62↑4.4% | 0.60↑11.0% | 0.54↑15.2% | 0.47↑261.2% | 0.13 | |
| EBITDA | -79↓60.9% | -49↑26.1% | -66↓5.5% | -63↓76.0% | -36 | |
| EBIT | -79↓60.3% | -50↑25.8% | -67↓5.6% | -63↓76.7% | -36 | |
| Interest & Other Income | ||||||
| Net Interest Income | 10↓24.4% | 13 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 10↓24.4% | 13 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -13↓13.0% | -11↓164.4% | -4 | 0.00 | |
| Other Income / Expenses | 10↓24.4% | 13↑13.0% | 11↑164.4% | 4↑1337.9% | 0.30 | |
| Income Before Tax | -70↓40.7% | -50↑25.8% | -67↓5.6% | -63↓78.2% | -36 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -70↓40.7% | -50↑25.8% | -67↓5.6% | -63↓78.2% | -36 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -70↓40.7% | -50↑25.8% | -67↓5.6% | -63↓78.2% | -36 | |
| Bottom-Line Net Income | -70↓40.7% | -50↑25.8% | -67↓5.6% | -63↓78.2% | -36 | |
| EPS (Basic) | -1.22↓38.6% | -0.88↑26.1% | -1.19↓4.4% | -1.14↓48.1% | -0.77 | |
| EPS (Diluted) | -1.22↓38.6% | -0.88↑26.1% | -1.19↓4.4% | -1.14↓48.1% | -0.77 | |
| Weighted Average Shares | 57↑1.3% | 57↑1.1% | 56↑0.5% | 56↑21.3% | 46 | |
| Weighted Average Diluted Shares | 57↑1.3% | 57↑1.1% | 56↑0.5% | 56↑21.3% | 46 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.